437 related articles for article (PubMed ID: 30151728)
41. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
42. How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
Sukkar L; Young T; Jardine MJ
Kidney Blood Press Res; 2020; 45(6):823-836. PubMed ID: 33271545
[TBL] [Abstract][Full Text] [Related]
43. Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.
Sharma A; Butler J; Zieroth S; Giannetti N; Verma S
Diabet Med; 2019 Dec; 36(12):1550-1561. PubMed ID: 31536660
[TBL] [Abstract][Full Text] [Related]
44. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
45. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
46. Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure.
Packer M
Diabet Med; 2018 Jun; 35(6):707-713. PubMed ID: 29532519
[TBL] [Abstract][Full Text] [Related]
47. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
48. [Not Available].
Toft E; Rydén M
Lakartidningen; 2018 Feb; 115():. PubMed ID: 29461566
[TBL] [Abstract][Full Text] [Related]
49. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
Kaul S
Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
[TBL] [Abstract][Full Text] [Related]
50. Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.
Shin JI
Curr Diab Rep; 2019 Jul; 19(8):54. PubMed ID: 31286271
[TBL] [Abstract][Full Text] [Related]
51. Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
Cheng JWM; Badreldin HA; Patel DK; Bhatt SH
Curr Med Res Opin; 2017 Jun; 33(6):985-992. PubMed ID: 28097882
[TBL] [Abstract][Full Text] [Related]
52. Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.
Chawla H; Tandon N
Am J Cardiovasc Drugs; 2017 Jun; 17(3):203-215. PubMed ID: 28197977
[TBL] [Abstract][Full Text] [Related]
53. [Diabetes Mellitus Type 2: Recent Publications and New Drugs].
Elbelt U
Dtsch Med Wochenschr; 2018 Jun; 143(11):772-776. PubMed ID: 29807374
[TBL] [Abstract][Full Text] [Related]
54. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2.
Yandrapalli S; Malik A; Horblitt A; Pemmasani G; Aronow WS; Frishman WH
Cardiol Rev; 2020; 28(5):219-235. PubMed ID: 32271194
[TBL] [Abstract][Full Text] [Related]
55. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
Guo WQ; Li L; Su Q; Dai WR; Ye ZL
Value Health; 2017 Dec; 20(10):1427-1430. PubMed ID: 29241903
[TBL] [Abstract][Full Text] [Related]
56. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
[TBL] [Abstract][Full Text] [Related]
57. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
[TBL] [Abstract][Full Text] [Related]
58. Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose-lowering agents: A population-based community study from the Shizuoka Kokuho database.
Kohsaka S; Kumamaru H; Nishimura S; Shoji S; Nakatani E; Ichihara N; Yamamoto H; Miyachi Y; Miyata H
J Diabetes Investig; 2021 Aug; 12(8):1452-1461. PubMed ID: 33345452
[TBL] [Abstract][Full Text] [Related]
59. Cardiovascular safety of therapies for type 2 diabetes.
Gupta P; White WB
Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
[TBL] [Abstract][Full Text] [Related]
60. Safety and cardiometabolic efficacy of novel antidiabetic drugs.
Michaud L; Seplowe M; Meir J; Aronow WS
Expert Opin Drug Saf; 2023 Feb; 22(2):119-124. PubMed ID: 36877138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
